

| ID   | Research Ethics Committee Reference Number | Integrated Research Applications System Number | Name of Trial   | Target Number of Patients Agreed? | Minimum Number of Patients Agreed (Enter Same in Both if Only One Number) | Maximum Number of Patients Agreed (Enter Same in Both if Only One Number) | Target Date to Recruit Patients Agreed? | Date Agreed to recruit number of patients | Total Number of Patients Recruited At The Agreed Target Date | Date That The Trial Closed To Recruitment | Total Number Of Study Participants Recruited | Reason for Closure Of Trial | Comments  | Errors | Check Rows to check on sponsor submission |
|------|--|--|---|-----------------------------------|---|---|---|---|--|---|--|-----------------------------|---|--------|---|
| 2143 | 15/NE/0014                                 | 192732   | A 12-Week Study to Assess the Efficacy and Safety of Af-219 in Subjects with Type 2 Diabetes Mellitus   | Number Agreed                     |   | 6   | 6                                       | Date Agreed 15/07/2016                    | 13   | 15/07/2016                                | 13   | Recruitment Finished        | We recruited over target because recruitment was competitive  |        | <input type="checkbox"/>                  |
| 2144 | 15/FE/0405                                 | 189187   | Odyssey DM: A Randomized, DoubleBlind, PlaceboControlled, Parallel Group Study of the Efficacy and Safety of the Novel Oral SGLT2 Inhibitor, Dapagliflozin, in Patients with Type 2 Diabetes Mellitus               | Number Agreed                     |   | 5   | 5                                       | Date Agreed 01/07/2016                    | 3  | 15/08/2016                                | 3  | Recruitment Finished        | We did not meet target due to unexpected staff shortages and lower than anticipated screening.  |        | <input type="checkbox"/>                  |
| 2145 | 15/EM/0473                                 | 187884   | A randomized, open-label, active-controlled, Phase II study of intravenous anesthetic propofol in patients with obstructive sleep apnea   | Number Agreed                     |   | 3   | 3                                       | Date Agreed 31/03/2017                    | 11   | 09/12/2016                                | 11   | Recruitment Finished        | Recruitment was closed early but we still exceeded the target.  |        | <input type="checkbox"/>                  |
| 2146 | 15/SC/0521                                 | 185322   | ABOUND: A Phase 2, randomized, open-label, multicenter study to assess safety and efficacy of the novel oral SGLT2 inhibitor, dapagliflozin, in patients with type 2 diabetes mellitus                              | Number Agreed                     |   | 4   | 4                                       | Date Agreed 01/04/2015                    | 1  | 05/12/2016                                | 1  | Withdrawn By Sponsor        | Study closed early as sponsor reached their overall target before we had chance to recruit target number agreed. Sponsor holds up with protocol amendment also.   |        | <input type="checkbox"/>                  |
| 2147 | 15/DL/0361                                 | 193836   | DALISADE: Peanut Allergy Oral Immunotherapy Study of All101 for Desensitization   | Number Agreed                     |   | 5   | 5                                       | Date Agreed 16/11/2016                    | 3  | 16/11/2016                                | 3  | Recruitment Finished        | Limited number of eligible patients seen there are multiple screen failures.  |        | <input type="checkbox"/>                  |
| 2148 | 15/NW/0698                                 | 183781   | Regain - TITL: A twenty six week, randomized, open-label, 2-arm parallel group study of the efficacy and safety of the novel oral SGLT2 inhibitor, dapagliflozin, in patients with type 2 diabetes mellitus         | Number Agreed                     |   | 4   | 4                                       | Date Agreed 07/10/2016                    | 1  | 07/10/2016                                | 1  | Recruitment Finished        | No eligible patients seen and short recruitment period.   |        | <input type="checkbox"/>                  |
| 2149 | 15/NW/0697                                 | 183760   | Reath - A twenty six week, randomized, open-label, 2-arm parallel group study of the efficacy and safety of the novel oral SGLT2 inhibitor, dapagliflozin, in patients with type 2 diabetes mellitus                | Range Agreed                      |   | 4   | 5                                       | Date Agreed 07/10/2016                    | 5  | 07/10/2016                                | 5  | Recruitment Finished        |   |        | <input type="checkbox"/>                  |
| 2150 | 15/WA/0241                                 | 185742   | Quest 2 - A multi-centre, randomised, double blind, placebo controlled, parallel group study of the efficacy and safety of the novel oral SGLT2 inhibitor, dapagliflozin, in patients with type 2 diabetes mellitus | Number Agreed                     |   | 4   | 4                                       | Date Agreed 19/12/2016                    | 2  | 19/12/2016                                | 2  | Recruitment Finished        | No eligible patients seen and multiple screen failures.   |        | <input type="checkbox"/>                  |
| 2151 | 15/SC/0115                                 | 167694   | Harmony - A long term, randomised, double blind, placebo controlled study to assess the efficacy and safety of the novel oral SGLT2 inhibitor, dapagliflozin, in patients with type 2 diabetes mellitus             | Range Agreed                      |   | 8   | 10                                      | Date Agreed 31/12/2016                    | 6  | 23/12/2016                                | 6  | Recruitment Finished        | Study recruitment closed early  |        | <input type="checkbox"/>                  |
| 2152 | 15/FE/0136                                 | 170557   | A randomised, open-label, multicentre study of liposomal amikacin for inhalation in patients with cystic fibrosis   | Number Agreed                     |   | 1   | 3                                       | Date Agreed 04/11/2016                    | 0  | 04/11/2016                                | 0  | Recruitment Finished        | No eligible patients seen and rare condition / patient group.   |        | <input type="checkbox"/>                  |
| 2153 | 15/NW/0331                                 | 184594   | Heart Mate 3  | Range Agreed                      |   | 15  | 20                                      | Date Agreed 30/01/2017                    | 20   | 30/01/2017                                | 20   | Recruitment Finished        |   |        | <input type="checkbox"/>                  |
| 2154 | 15/EM/0309                                 | 184678   | CLEARCUT V8475  | Number Agreed                     |   | 3   | 3                                       | Date Agreed 28/02/2017                    | 3  | 06/03/2017                                | 3  | Recruitment Finished        |   |        | <input type="checkbox"/>                  |
| 2155 | 15/NW/0248                                 | 186070   | Veritas V144-651-110  | Number Agreed                     |   | 8   | 8                                       | Date Agreed 25/10/2016                    | 8  | 15/11/2016                                | 8  | Recruitment Finished        |   |        | <input type="checkbox"/>                  |
| 2156 | 15/SC/0018                                 | 191262   | EMPRE CT4430  | Number Agreed                     |   | 4   | 4                                       | Date Agreed 31/03/2017                    | 4  | 31/03/2017                                | 4  | Recruitment Finished        |   |        | <input type="checkbox"/>                  |
| 2157 | 15/NW/0255                                 | 163780   | TANGO II  | Number Agreed                     |   | 4   | 4                                       | Date Agreed 31/12/2017                    | 1  | 08/02/2017                                | 1  | Withdrawn By Sponsor        | Recruitment closed early by the sponsor as they decided to only keep open few sites to finish the recruitment   |        | <input type="checkbox"/>                  |
| 2158 | 15/LQ/1500                                 | 187068   | BI 1199 229   | Number Agreed                     |   | 4   | 4                                       | Date Agreed 31/01/2017                    | 6  | 14/03/2017                                | 6  | Recruitment Finished        | We recruited over target because recruitment was competitive, sponsor agreed to recruiting over target.   |        | <input type="checkbox"/>                  |
| 2159 | 15/NW/0787                                 | 216022   | ALBATROSS   | Number Agreed                     |   | 2   | 2                                       | Date Agreed 15/06/2017                    | 4  | 22/06/2017                                | 4  | Recruitment Finished        | We recruited over target because recruitment was competitive, sponsor agreed to recruiting over target.   |        | <input type="checkbox"/>                  |
| 2160 | 15/NW/0247                                 | 186460   | Boschinger Biosimilar   | Number Agreed                     |   | 5   | 5                                       | Date Agreed 02/02/2017                    | 0  | 02/02/2017                                | 0  | Recruitment Finished        | We did not recruit any patients due to study approval being delayed by sponsor amendment and delays with equipment. Therefore, available recruitment period shortened which prevented us from meeting target. |        | <input type="checkbox"/>                  |
| 2173 | 15/SC/0141                                 | 204763   | ZH-203  | Range Agreed                      |   | 4   | 5                                       | Date Agreed 31/10/2017                    | 1  | 17/05/2017                                | 1  | Withdrawn By Sponsor        | Sponsor closed recruitment early due to reaching their overall recruitment target for the study.  |        | <input type="checkbox"/>                  |